Community/Retail

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.

The pharmacy supply chain and reimbursement marketplace are broken, manufacturers are throwing up their hands and getting into the vertical integration scrum

Individuals with persistent asthma and at least 1 complex comorbidity were more likely to use telemedicine, the results of the study showed.

Teplizumab is indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients 8 years of age and older with stage 2 T1D.

Promising data have emerged suggesting a significant weight loss benefit for patients using GLP-1 agonists and GLP-1/GIP dual agonists.

“I see clinical pharmacy specialists (CPS) to be more like the frontline folks that would pretty much work very closely with the providers,” according to a CPS at City of Hope.

Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous.

Diabetes is a known risk factor for cognitive decline and small vessel disease.

Vitamin D preserved insulin-producing cells and cell function, which can reduce complications in young patients.

They also compared the approach of the European Medicines Agency and the FDA in drug approvals.

The at-home test offers the availability to assess for all viruses using one tool.

Findings emphasize the importance of further research on effective and safe alternative treatments for MDD in children and adolescents, specifically in patients who are refractory to nonpharmacologic treatment and/or standard of care antidepressants

Artificial intelligence (AI) recommendations resulted in fewer recurrent strokes, heart attacks, or vascular death within 3 months of a previous ischemic stroke.

This episode highlights how celebrity endorsements and local influencers can be leveraged to address vaccine hesitancy by shaping attitudes, but also must account for factors like audience trust and the potential for both benefits and limitations.

The continuous glucose monitoring system will be available for purchase online and without a prescription starting in summer 2024.

Denosumab-bbdz (Wyost; Sandoz) and denosumab-bbdz (Jubbonti; Sandoz) are approved as interchangeable for all indications of denosumab (Xgeva and Prolia; Amgen).

This designation makes CBL-514 the first drug to receive both Orphan Drug Designation and Fast Track Designation for the treatment of Dercum disease.

Investigators also found that those with community-acquired, radiology-confirmed pneumonia with lower respiratory tract infections had worse outcomes.

Children with normal weight had different community relationships compared to children with overweight or obesity.

In the study, investigators found superior kidney outcomes with injectable semaglutide (Ozempic) for individuals with type 2 diabetes and chronic kidney disease.

Laws can help eliminate common barriers to transparency but are not the only way to achieve health care transparency.

According to the researchers, making changes to the daylight saving time system to accommodate heart health is unnecessary.

In some instances, metabolites can predict risk in patients who still have normal glucose biomarkers.

AAO-HNSF guideline development group included 17 panel members, including experts from otolaryngology and allergy, those who have knowledge in clinical practice guideline development, and patient representatives.

Omega-3s are important during pregnancy because they can reduce risk of preeclampsia and other negative health outcomes.

Investigators at Duke University and the University of North Carolina determine what causes recurrent UTIs, even after antibiotics cleared the bacterial infection.

Only 9% of older adults who reside in the United States had been vaccinated to protect themselves from RSV this fall and winter.

Study findings suggest that biomarkers could provide greater insight into different disease mechanisms and how treatments options could be more beneficial for certain patients.

Jon Martin, US commercial lead of biosimilars at Organon, discusses how making their biosimilar Hadlima the preferred product on the Veteran Affairs formulary will help lower treatment costs.